Saleh K, Khalife N, Arbab A, Khoury R, Chahine C, Ibrahim R
Biomedicines. 2025; 12(12.
PMID: 39767716
PMC: 11674015.
DOI: 10.3390/biomedicines12122810.
Massariol Pimenta T, Carlos de Souza J, da Silva Martins B, Silva Butzene S, Simoes Padilha J, Ganho Marcal M
Front Pharmacol. 2024; 15:1490896.
PMID: 39564107
PMC: 11573523.
DOI: 10.3389/fphar.2024.1490896.
Diorio C, Hernandez-Miyares L, Espinoza D, Banwell B, Bar-Or A, DiNofia A
Blood. 2024; 144(13):1387-1398.
PMID: 38905637
PMC: 11830968.
DOI: 10.1182/blood.2024023933.
Perna F, Parekh S, Diorio C, Smith M, Subklewe M, Mehta R
Blood Adv. 2024; 8(16):4348-4358.
PMID: 38861351
PMC: 11375260.
DOI: 10.1182/bloodadvances.2024013044.
Brudno J, Kochenderfer J
Nat Rev Clin Oncol. 2024; 21(7):501-521.
PMID: 38769449
PMC: 11529341.
DOI: 10.1038/s41571-024-00903-0.
Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
Yoo J
Blood Res. 2023; 58(S1):S20-S28.
PMID: 36891576
PMC: 10133856.
DOI: 10.5045/br.2023.2023026.
Dasatinib for treatment of CAR T-cell therapy-related complications.
Baur K, Heim D, Beerlage A, Poerings A, Kopp B, Medinger M
J Immunother Cancer. 2022; 10(12).
PMID: 36455991
PMC: 9717332.
DOI: 10.1136/jitc-2022-005956.
Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes.
Clubb J, Gao T, Chen Y
Clin Cancer Res. 2022; 29(8):1390-1402.
PMID: 36454122
PMC: 10106357.
DOI: 10.1158/1078-0432.CCR-22-1491.
Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003-2018.
West J, Stilwell P, Liu H, Ban L, Bythell M, Card T
Hemasphere. 2022; 6(11):e797.
PMID: 36340911
PMC: 9624441.
DOI: 10.1097/HS9.0000000000000797.
Cardiovascular disease and chimeric antigen receptor cellular therapy.
Rao A, Stewart A, Eljalby M, Ramakrishnan P, Anderson Jr L, Awan F
Front Cardiovasc Med. 2022; 9:932347.
PMID: 36211558
PMC: 9538377.
DOI: 10.3389/fcvm.2022.932347.
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.
Mann H, Comenzo R
Onco Targets Ther. 2022; 15:799-813.
PMID: 35912273
PMC: 9327779.
DOI: 10.2147/OTT.S305429.
DLBCL 1L-What to Expect beyond R-CHOP?.
Stegemann M, Denker S, Schmitt C
Cancers (Basel). 2022; 14(6).
PMID: 35326604
PMC: 8946010.
DOI: 10.3390/cancers14061453.
Critical illness in patients with hematologic malignancy: a population-based cohort study.
Ferreyro B, Scales D, Wunsch H, Cheung M, Gupta V, Saskin R
Intensive Care Med. 2021; 47(10):1104-1114.
PMID: 34519845
DOI: 10.1007/s00134-021-06502-2.
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments.
Ramakrishnan Geethakumari P, Ramasamy D, Dholaria B, Berdeja J, Kansagra A
Curr Hematol Malig Rep. 2021; 16(4):345-356.
PMID: 34089485
PMC: 8179081.
DOI: 10.1007/s11899-021-00635-3.
